McNeil
This article was originally published in The Tan Sheet
Executive Summary
Firm agrees to acquire the technology for the Nicotrol nicotine patch along with a number of other drug delivery systems from Cygnus for up to $75 mil. in cash. McNeil Consumer Healthcare markets Nicotrol in the U.S. Cygnus is retaining the assets related to a nicotine patch under development and one other early stage product
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning